GSH‐Responsive Dnase‐I‐Loaded MnOx Nanoplatforms for Combined Protein‐Chemodynamic Therapy. Issue 2 (29th December 2022)

• Record Type: Journal Article
• Authors: Xu, Zhongsheng; Zhang, Liang; Sun, Tao; Zhou, Chunyu; Xiao, Shilin; Yin, Hong; Gong, Mingfu; Zhang, Dong; Liu, Yun
• Is Part Of: Advanced nanobiomed research. Volume 3:Issue 2(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-29
• Subjects: combined therapeutics -- Dnase-I -- MnOx nanoflowers -- protein therapeutics; Nanomedicine -- Periodicals; Biomedical engineering -- Periodicals; Biomedical materials -- Periodicals; Nanomedicine; Nanostructures; Bioengineering; Biocompatible Materials; Electronic journals; Periodicals; Periodical; 610.28
• DOI: 10.1002/anbr.202200120
• Languages: English
• ISSNs: 2699-9307

Abstract

Abstract : The effective delivery of protein therapeutics remains a major challenge. Here, the novel nanoplatforms with bovine serum albumin (BSA)‐coated, Dnase‐1‐loaded MnO x nanoflowers are developed (denominated MD@BSA). These MD@BSA nanoplatforms present a highly efficient protein loading and effective delivery Dnase‐I into tumor cells. Under the glutathione (GSH) overexpression environment, MD@BSA is degradable, resulting in Dnase‐1 and Mn 2+ release for combining protein therapeutics and chemodynamic therapy (CDT), and the GSH‐responsive MR imaging in vivo and vitro that could be used to trace and evaluate the severity of tumor for therapeutic regimen adjustment. This method offers a facile and GSH‐responsive strategy for both delivering proteins and enhanced treatment effect via combined protein‐CDT, which may contribute to the clinical application of protein therapeutics in the future. Abstract : MD@BSA, for glutathione‐associated tumor diagnosis and treatment, is successfully prepared. The distinctive advantages of MD@BSA are highly efficient protein loading, magnetic resonance imaging‐based tumor diagnosis, combined protein‐ and chemodynamic therapy‐based tumor treatment, biodegradability, and high biocompatibility. Both in vitro and in vivo studies systematically demonstrate that MD@BSA could efficiently suppress tumor growth, damaging tumor cells via ferroptosis and apoptosis.